Dauntless Pharmaceuticals formed in 2016, and its founders said the Sofinnova Ventures-backed firm planned to take a new approach to building biotechs.

Instead of advancing a broad stable of early-stage drug candidates under the same roof, Dauntless aimed to set up each asset within its own company. The idea was that when it came time to sell or license an investigational drug, it would be easier to get it out the door if it wasn’t entangled with other, ongoing R&D.

Now its founders are throwing out that game plan and reverting to the traditional biotech model. Olivier Laurent and Joel… Read more »